NQ 2030
Alternative Names: NQ-2030Latest Information Update: 20 Jul 2024
At a glance
- Originator Novaliq
- Class Anti-inflammatories; Eye disorder therapies; Small molecules
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic retinopathy
Most Recent Events
- 11 Jul 2024 Preclinical trials in Diabetic retinopathy in Germany (Opthalmic) (Novaliq pipeline, July 2024)
- 11 Jul 2024 Novaliq targets a pre-IND meeting with the US FDA in 2025 for at least one API for a topical drug product for patients with non-proliferative Diabetic retinopathy therapy (Novaliq pipeline, July 2024)